|
GB581334A
(en)
|
1943-09-29 |
1946-10-09 |
Francis Henry Swinden Curd |
New pyrimidine compounds
|
|
JPS4921149B1
(enExample)
|
1970-12-28 |
1974-05-30 |
|
|
|
JPS4921148B1
(enExample)
|
1970-12-28 |
1974-05-30 |
|
|
|
AT340933B
(de)
|
1973-08-20 |
1978-01-10 |
Thomae Gmbh Dr K |
Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
|
|
DE2341925A1
(de)
|
1973-08-20 |
1975-03-06 |
Thomae Gmbh Dr K |
Neue pyrimidinderivate und verfahren zu ihrer herstellung
|
|
US4994386A
(en)
|
1987-07-13 |
1991-02-19 |
Pharmacia Diagnostics, Inc. |
Production of HBLV virus in the HSB-2 cell line
|
|
US4929726A
(en)
|
1988-02-09 |
1990-05-29 |
Georgia State University Foundation, Inc. |
Novel diazines and their method of preparation
|
|
EP0330263A1
(en)
|
1988-02-25 |
1989-08-30 |
Merck & Co. Inc. |
Piperazinylalkylpyrimidines as hypoglycemic agents
|
|
GB9012311D0
(en)
|
1990-06-01 |
1990-07-18 |
Wellcome Found |
Pharmacologically active cns compounds
|
|
CA2065443A1
(en)
|
1990-07-03 |
1992-01-04 |
Akira Mizuchi |
Pyrimidine compound and pharmaceutically acceptable salts thereof
|
|
CA2190973C
(en)
|
1995-04-13 |
2001-06-19 |
Yasuo Konno |
Novel 4,6-diarylpyrimidine derivatives and salts thereof
|
|
JP3734907B2
(ja)
|
1996-12-19 |
2006-01-11 |
富士写真フイルム株式会社 |
現像処理方法
|
|
CA2297326C
(en)
|
1997-07-24 |
2007-03-20 |
Zenyaku Kogyo Kabushiki Kaisha |
Heterocyclic compound and antitumor agent containing the same as active component
|
|
JPH11158073A
(ja)
|
1997-09-26 |
1999-06-15 |
Takeda Chem Ind Ltd |
アデノシンａ３拮抗剤
|
|
US6440965B1
(en)
|
1997-10-15 |
2002-08-27 |
Krenitsky Pharmaceuticals, Inc. |
Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
|
|
US6150362A
(en)
|
1997-12-12 |
2000-11-21 |
Henkin; Jack |
Triazine angiogenesis inhibitors
|
|
DE69906397T2
(de)
|
1998-01-16 |
2004-02-19 |
F. Hoffmann-La Roche Ag |
Benzosulfonderivate
|
|
JP4533534B2
(ja)
|
1998-06-19 |
2010-09-01 |
ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド |
グリコーゲンシンターゼキナーゼ３のインヒビター
|
|
US7045519B2
(en)
|
1998-06-19 |
2006-05-16 |
Chiron Corporation |
Inhibitors of glycogen synthase kinase 3
|
|
US6495558B1
(en)
|
1999-01-22 |
2002-12-17 |
Amgen Inc. |
Kinase inhibitors
|
|
CA2359680A1
(en)
|
1999-01-22 |
2000-07-27 |
David M. Armistead |
Kinase inhibitors
|
|
EP1206265B1
(en)
|
1999-06-30 |
2003-11-12 |
Merck & Co., Inc. |
Src kinase inhibitor compounds
|
|
EP1194152A4
(en)
|
1999-06-30 |
2002-11-06 |
Merck & Co Inc |
Links to SRC kinase inhibition
|
|
US6329380B1
(en)
|
1999-06-30 |
2001-12-11 |
Merck & Co., Inc. |
SRC kinase inhibitor compounds
|
|
JP2003505384A
(ja)
|
1999-07-15 |
2003-02-12 |
ファーマコピーア，インコーポレーティッド |
ブラジキニンｂ１受容体アンタゴニスト
|
|
JP2001089452A
(ja)
|
1999-09-22 |
2001-04-03 |
Sankyo Co Ltd |
ピリミジン誘導体
|
|
AU2001237041B9
(en)
|
2000-02-17 |
2005-07-28 |
Amgen Inc. |
Kinase inhibitors
|
|
JP5074653B2
(ja)
|
2000-03-29 |
2012-11-14 |
サイクラセル リミテッド |
２−置換４−ヘテロアリール−ピリミジンおよび増殖性障害におけるその使用
|
|
CN1186324C
(zh)
|
2000-04-27 |
2005-01-26 |
山之内制药株式会社 |
稠合杂芳基衍生物
|
|
AU2001241142B2
(en)
|
2000-04-28 |
2005-09-22 |
Tanabe Seiyaku Co., Ltd. |
Cyclic compounds
|
|
CA2409762A1
(en)
|
2000-06-23 |
2002-01-03 |
Donald J.P. Pinto |
Heteroaryl-phenyl substituted factor xa inhibitors
|
|
CN100506801C
(zh)
|
2000-09-06 |
2009-07-01 |
诺华疫苗和诊断公司 |
糖元合成酶激酶3的抑制剂
|
|
AU2001296871A1
(en)
|
2000-09-15 |
2002-03-26 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
SE0004053D0
(sv)
|
2000-11-06 |
2000-11-06 |
Astrazeneca Ab |
N-type calcium channel antagonists for the treatment of pain
|
|
HUP0400639A3
(en)
|
2000-12-21 |
2010-03-29 |
Vertex Pharma |
Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
|
|
WO2002062766A2
(en)
|
2001-02-07 |
2002-08-15 |
Millennium Pharmaceuticals, Inc. |
Melanocortin-4 receptor binding compounds and methods of use thereof
|
|
WO2002064096A2
(en)
|
2001-02-16 |
2002-08-22 |
Tularik Inc. |
Methods of using pyrimidine-based antiviral agents
|
|
JP2004531571A
(ja)
|
2001-05-25 |
2004-10-14 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
サイトカイン生産のインヒビターとしてのカルバメート及びオキサミド化合物
|
|
HUP0402352A2
(hu)
|
2001-06-19 |
2005-02-28 |
Bristol-Myers Squibb Co. |
Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
|
|
US6603000B2
(en)
|
2001-07-11 |
2003-08-05 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Synthesis for heteroarylamine compounds
|
|
WO2003030909A1
(en)
|
2001-09-25 |
2003-04-17 |
Bayer Pharmaceuticals Corporation |
2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
|
|
EP1485100B1
(en)
|
2002-03-15 |
2010-05-05 |
Vertex Pharmaceuticals Incorporated |
Azinylaminoazoles as inhibitors of protein kinases
|
|
WO2003078426A1
(en)
|
2002-03-15 |
2003-09-25 |
Vertex Pharmaceuticals, Inc. |
Azolylaminoazine as inhibitors of protein kinases
|
|
ATE365733T1
(de)
|
2002-03-15 |
2007-07-15 |
Vertex Pharma |
Zusammensetzungen brauchbar als protein-kinase- inhibitoren
|
|
EP1485380B1
(en)
|
2002-03-15 |
2010-05-19 |
Vertex Pharmaceuticals Incorporated |
Azolylaminoazines as inhibitors of protein kinases
|
|
US20040082627A1
(en)
|
2002-06-21 |
2004-04-29 |
Darrow James W. |
Certain aromatic monocycles as kinase modulators
|
|
WO2004029204A2
(en)
|
2002-09-27 |
2004-04-08 |
Merck & Co., Inc. |
Substituted pyrimidines
|
|
CA2501685A1
(en)
|
2002-10-08 |
2004-04-22 |
Massachusetts Institute Of Technology |
Compounds for modulation of cholesterol transport
|
|
US7223870B2
(en)
|
2002-11-01 |
2007-05-29 |
Pfizer Inc. |
Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
|
|
PT2316831E
(pt)
|
2002-11-21 |
2013-06-06 |
Novartis Ag |
2-(morfolin-4-il)pirimidinas como inibidores da fosfatidilinositol (pi) quinase e a sua utilização no tratamento do cancro
|
|
CA2514733A1
(en)
|
2003-02-28 |
2004-09-16 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
|
|
CN1791580A
(zh)
|
2003-03-24 |
2006-06-21 |
麦克公司 |
联芳基取代的6元杂环钠通道阻滞剂
|
|
US20050014753A1
(en)
|
2003-04-04 |
2005-01-20 |
Irm Llc |
Novel compounds and compositions as protein kinase inhibitors
|
|
CA2520323C
(en)
|
2003-04-09 |
2013-07-09 |
Exelixis, Inc. |
Tie-2 modulators and methods of use
|
|
EP1651619A1
(en)
|
2003-07-15 |
2006-05-03 |
Neurogen Corporation |
Substituted pyrimidin-4-ylamin analogues as vanilloid receptor ligands
|
|
EP1644358A2
(en)
|
2003-07-16 |
2006-04-12 |
Neurogen Corporation |
Biaryl piperazinyl-pyridine analogues
|
|
PE20050952A1
(es)
*
|
2003-09-24 |
2005-12-19 |
Novartis Ag |
Derivados de isoquinolina como inhibidores de b-raf
|
|
AU2005232745A1
(en)
|
2004-04-13 |
2005-10-27 |
Astellas Pharma Inc. |
Polycyclic pyrimidines as potassium ion channel modulators
|
|
GB0415364D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
GB0415365D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
MY145822A
(en)
|
2004-08-13 |
2012-04-30 |
Neurogen Corp |
Substituted biaryl piperazinyl-pyridine analogues
|
|
JP2008521900A
(ja)
*
|
2004-11-30 |
2008-06-26 |
アムジエン・インコーポレーテツド |
キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用
|
|
EP1824839A2
(en)
|
2004-12-13 |
2007-08-29 |
Neurogen Corporation |
Substituted biaryl analogues
|
|
CN101080228A
(zh)
|
2004-12-13 |
2007-11-28 |
神经能质公司 |
哌嗪基－吡啶类似物
|
|
AU2005321966B2
(en)
|
2004-12-28 |
2011-11-17 |
Atnx Spv, Llc |
Compositions and methods of treating cell proliferation disorders
|
|
AU2006206246A1
(en)
|
2005-01-19 |
2006-07-27 |
Neurogen Corporation |
Heteroaryl substituted piperazinyl-pyridine analogues
|
|
MX2007010404A
(es)
|
2005-02-25 |
2008-01-11 |
Kudos Pharm Ltd |
Hidrazinometilo, hidrazonometilo y compuestos heterociclicos de 5 miembros que actuan como inhibidores de mtor y su uso como agentes anti-cancer.
|
|
JP2008536950A
(ja)
|
2005-04-18 |
2008-09-11 |
ニューロジェン・コーポレーション |
置換ヘテロアリールのｃｂ１拮抗薬
|
|
GB2431156A
(en)
|
2005-10-11 |
2007-04-18 |
Piramed Ltd |
1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
|
|
WO2007080382A1
(en)
|
2006-01-11 |
2007-07-19 |
Astrazeneca Ab |
Morpholino pyrimidine derivatives and their use in therapy
|
|
JO2660B1
(en)
*
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
WO2007120897A2
(en)
*
|
2006-04-13 |
2007-10-25 |
The Trustees Of Columbia University In The City Of New York |
Compositions and intraluminal devices for inhibiting vascular stenosis
|
|
AR064571A1
(es)
|
2006-12-28 |
2009-04-08 |
Basf Ag |
Pirimidinas sustituidas en posicion 2 por heterociclos nitrogenados, medicamentos y composiciones farmaceuticas que las contienen y usos de las mismas en el tratamiento del cancer.
|
|
EP2118087B1
(en)
|
2007-02-06 |
2012-03-28 |
Novartis AG |
Pi 3-kinase inhibitors and methods of their use
|
|
US7957951B2
(en)
|
2007-03-16 |
2011-06-07 |
Robert Bosch Gmbh |
Address translation system for use in a simulation environment
|
|
BRPI0814818A2
(pt)
|
2007-07-09 |
2019-09-10 |
Astrazeneca Ab |
composto, uso de um composto, métodos para produzir um efeito anti-proliferativo e um efeito inibitório de mtor quinase em uma animal de sangue quente, método para tratar doenças, e, composição farmacêutica
|
|
WO2009066084A1
(en)
|
2007-11-21 |
2009-05-28 |
F. Hoffmann-La Roche Ag |
2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
|
|
KR20100131446A
(ko)
|
2008-03-05 |
2010-12-15 |
노파르티스 아게 |
Ｅｇｆｒ 의존성 질환 또는 ｅｇｆｒ 족 구성원을 표적으로 하는 작용제에 대한 내성을 획득한 질환의 치료를 위한 피리미딘 유도체의 용도
|
|
BRPI0909082A2
(pt)
|
2008-03-26 |
2019-02-26 |
Novartis Ag |
imidazoquinolinas e derivados de pirimidina como moduladores potentes de processos angiogênicos acionados por vegf
|
|
EP2276750A2
(en)
|
2008-03-27 |
2011-01-26 |
Auckland Uniservices Limited |
Substituted pyrimidines and triazines and their use in cancer therapy
|
|
JP5277256B2
(ja)
|
2008-04-09 |
2013-08-28 |
田辺三菱製薬株式会社 |
ｍａｘｉ−Ｋチャネル開口薬としてのピリミジン、ピリジン及びトリアジン誘導体
|
|
GB0815369D0
(en)
|
2008-08-22 |
2008-10-01 |
Summit Corp Plc |
Compounds for treatment of duchenne muscular dystrophy
|
|
EP2349275B1
(en)
|
2008-10-31 |
2017-03-08 |
Novartis AG |
Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor.
|
|
GB2465405A
(en)
|
2008-11-10 |
2010-05-19 |
Univ Basel |
Triazine, pyrimidine and pyridine analogues and their use in therapy
|
|
WO2010068863A2
(en)
|
2008-12-12 |
2010-06-17 |
Cystic Fibrosis Foundation Therapeutics, Inc. |
Pyrimidine compounds and methods of making and using same
|
|
JP5747440B2
(ja)
|
2009-02-06 |
2015-07-15 |
住友化学株式会社 |
ヒドラジド化合物及びその有害生物防除用途
|
|
RU2535217C2
(ru)
|
2009-02-06 |
2014-12-10 |
Ниппон Синяку Ко., Лтд. |
Производные аминопиразина и лекарственные средства
|
|
EP2406389B1
(en)
|
2009-03-13 |
2019-05-08 |
Agios Pharmaceuticals, Inc. |
Methods and compositions for cell-proliferation-related disorders
|
|
WO2010120994A2
(en)
|
2009-04-17 |
2010-10-21 |
Wyeth Llc |
Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
|
|
KR20120016247A
(ko)
|
2009-05-19 |
2012-02-23 |
다우 아그로사이언시즈 엘엘씨 |
진균 방제를 위한 화합물 및 방법
|
|
EP2532659A1
(en)
|
2009-07-07 |
2012-12-12 |
Pathway Therapeutics, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
|
WO2011017296A1
(en)
|
2009-08-04 |
2011-02-10 |
Schering Corporation |
4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
|
|
AR077999A1
(es)
|
2009-09-02 |
2011-10-05 |
Vifor Int Ag |
Antagonistas de pirimidin y triazin-hepcidina
|
|
WO2011031896A2
(en)
|
2009-09-09 |
2011-03-17 |
Avila Therapeutics, Inc. |
Pi3 kinase inhibitors and uses thereof
|
|
ES2642109T3
(es)
|
2009-12-09 |
2017-11-15 |
Agios Pharmaceuticals, Inc. |
Compuestos terapéuticamente activos para su uso en el tratamiento de cáncer caracterizados por tener una mutación de IDH
|
|
GB201004200D0
(en)
|
2010-03-15 |
2010-04-28 |
Univ Basel |
Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
|
|
AR081626A1
(es)
|
2010-04-23 |
2012-10-10 |
Cytokinetics Inc |
Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
|
|
AR081331A1
(es)
|
2010-04-23 |
2012-08-08 |
Cytokinetics Inc |
Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
|
|
WO2011133920A1
(en)
|
2010-04-23 |
2011-10-27 |
Cytokinetics, Inc. |
Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
|
|
WO2011143160A2
(en)
|
2010-05-10 |
2011-11-17 |
The Johns Hopkins University |
Metabolic inhibitor against tumors having an idh mutation
|
|
EP2593425B1
(en)
|
2010-07-16 |
2018-10-17 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compositions and their method of use
|
|
CN104987321A
(zh)
|
2010-10-01 |
2015-10-21 |
诺华有限公司 |
制造嘧啶衍生物的方法
|
|
SG189019A1
(en)
|
2010-10-18 |
2013-05-31 |
Cerenis Therapeutics Holding Sa |
Compounds, compositions and methods useful for cholesterol mobilisation
|
|
GB201106829D0
(en)
|
2011-04-21 |
2011-06-01 |
Proximagen Ltd |
Heterocyclic compounds
|
|
KR20140063509A
(ko)
|
2011-02-11 |
2014-05-27 |
다나-파버 캔서 인스티튜트 인크. |
과오종 종양 세포의 억제 방법
|
|
CN102827073A
(zh)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
治疗活性组合物和它们的使用方法
|
|
JP2014527542A
(ja)
|
2011-09-01 |
2014-10-16 |
ノバルティス アーゲー |
骨がんの治療に使用するためまたは原発がん細胞の骨への転移性播種を予防するためのｐｉ３ｋ阻害剤
|
|
JP6026544B2
(ja)
|
2011-09-27 |
2016-11-16 |
ノバルティス アーゲー |
変異体ｉｄｈの阻害剤としての３−ピリミジン−４−イル−オキサゾリジン−２−オン類
|
|
JP2014528446A
(ja)
|
2011-10-06 |
2014-10-27 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
１，３−置換アゼチジンｐｄｅ１０阻害剤
|
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
|
EP2849756A1
(en)
*
|
2012-05-16 |
2015-03-25 |
Novartis AG |
Dosage regimen for a pi-3 kinase inhibitor
|
|
WO2013184621A1
(en)
|
2012-06-06 |
2013-12-12 |
Novartis Ag |
Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
|
|
HK1211476A1
(en)
|
2012-08-16 |
2016-05-27 |
Novartis Ag |
Combination of pi3k inhibitor and c-met inhibitor
|
|
CN104736532B
(zh)
|
2012-10-23 |
2017-04-05 |
诺华股份有限公司 |
改进的生产5‑(2,6‑二‑4‑吗啉‑4‑嘧啶)‑4‑三氟甲基吡啶‑2‑胺的方法
|
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
|
KR20150127197A
(ko)
|
2013-03-14 |
2015-11-16 |
노파르티스 아게 |
돌연변이 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
|
|
HK1213251A1
(zh)
|
2013-03-14 |
2016-06-30 |
Novartis Ag |
作为突变idh抑制剂的3-嘧啶-4-基-恶唑烷-2-酮化合物
|
|
CN103483345B
(zh)
|
2013-09-25 |
2016-07-06 |
中山大学 |
Pi3k激酶抑制剂、包含其的药物组合物及其应用
|
|
CN103694218B
(zh)
|
2013-12-05 |
2016-04-27 |
中山大学 |
嘧啶化合物、pi3k抑制剂、包含pi3k抑制剂的药物组合物及应用
|